Home > Journals > Minerva Biotecnologica > Past Issues > Minerva Biotecnologica 2002 June;14(2) > Minerva Biotecnologica 2002 June;14(2):159-64

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints

MINERVA BIOTECNOLOGICA

A Journal on Biotechnology and Molecular Biology


Indexed/Abstracted in: EMBASE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 0,246


eTOC

 

REVIEWS  7th INTERNATIONAL CONFERENCE ON TRANSGLUTAMINASES AND PROTEIN CROSSLINKING REACTIONS
Ferrara (Italy), September 14-17, 2002


Minerva Biotecnologica 2002 June;14(2):159-64

language: English

Differentiation therapy of cancer. Transglutaminase as differentiative tool

Lenini A., Beninati S.

Department of Biology, University of Rome “Tor Vergata”, Rome, Italy


FULL TEXT  


Differentiation therapy is a new approach to the treatment of advanced or aggressive malignancies and may be significantly efficacious in the treatment of many types of cancer. Several research projects are focused on different approaches to the study of cancer cell differentiation, all of which serve to complement one another. Our experimental address in this field is the identification of new molecules able to induce cancer cell differentiation by enhancing transglutaminase (TGase) activity. Recently, retinoic acid and theophylline appeared particularly promising as inducers of differentiation in cultured melanoma cell lines. This overview will explore the potential mechanism(s) involved in the action of these molecules, evaluating the possibility of their therapeutical applications.

top of page

Publication History

Cite this article as

Corresponding author e-mail